Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ] - Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010
Mon, September 27, 2010
[ Mon, Sep 27th 2010 ] - Market Wire
Wellstar Announces New Website
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010

ARIAD to Present at the Jefferies Global SpecPharma and European Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. ecpharma-and-european-healthcare-conference.html
Published in Health and Fitness on Tuesday, September 28th 2010 at 4:45 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it is scheduled to present at the Jefferies Global SpecPharma and European Healthcare Conference being held in London, England. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Tuesday, October 5, 2010 at 12:30 p.m. local time.

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://investor.ariad.com ]. A replay of the presentation will be available on the ARIAD website approximately 24 hours after the presentation and will be archived for three weeks.

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need a" aggressive cancers where current therapies are inadequate. ARIADa™s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIADa™s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in pivotal Phase 2 clinical development in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information about the Company, please visit [ http://www.ariad.com ].


Publication Contributing Sources